Colorectal cancer prevention: Screening and the role of aspirin

Colorectal Cancer

Volumn 2, Issue 5, 2013, Pages 429-439

  Elwood, Peter C ^a   Steward, William P ^b   Galante, Julieta ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; B RAF KINASE; CYCLOOXYGENASE 2 INHIBITOR; PLACEBO; PROTON PUMP INHIBITOR;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; COLON CANCER; COLON HEMORRHAGE; COLON PERFORATION; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DIVERTICULOSIS; DRUG WITHDRAWAL; ESOPHAGUS RESECTION; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTION; HEMORRHOID; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HYPERTENSION; LOW DRUG DOSE; MISMATCH REPAIR; MORTALITY; OCCULT BLOOD; PATIENT COMPLIANCE; PEPTIC ULCER; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM POLYP; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIGMOIDOSCOPY; STOMACH HEMORRHAGE; STOMACH ULCER; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 84964270262     PISSN: 1758194X     EISSN: 17581958     Source Type: Journal    
DOI: 10.2217/crc.13.48     Document Type: Review

References (100)

1. NICE. The Diagnosis and Management of Colorectal Cancer: Full Guideline. NICE, London, UK (2011).
2. Walsh JM, Terdiman JP. Colorectal screening. JAMA 289, 1288-1296 (2003).
3. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: A necropsy study in Liverpool. Gut 23, 835-842 (1982).
4. Corley DA. The future of colon screening. Gastroenterology 14, 1956-1958 (2011).
5. Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick AM. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. Ann. Intern. Med. 135, 769-781 (2001).
6. Elwood PC, Cochrane AL, Burr ML et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br. Med. J. 1(5905), 436-440 (1974).
7. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations and medications: Case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 48, 4399-4404 (1988).
8. Elwood PC, Gallacher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates and cancer. Lancet 373, 1301-1309 (2003).
9. Cuzic J, Otto F, Baron JA et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: An international consensus statement. Lancet Oncol. 10, 501-507 (2009).
10. Flossman E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet 12 (369), 1603-1613 (2007).
11. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet 377, 31-41 (2011).
12. Rothwell PM, Wilson M, Elwin CE et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20 year follow-up of five randomised trials. Lancet 376, 1741-1750 (2010).
13. Rothwell PM, Price JF, Fowkes FG et al. Short-term effects of daily aspirin on cancer incidence, mortality and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised trials. Lancet 379, 1602-1612 (2012).
14. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet 379, 1591-1601 (2012).
15. Mills EJ, Wu P, Alberton M, Kanters S, Lanas A, Lester R. Low-dose aspirin and cancer mortality: A meta-analysis of randomised trials. Am. J. Med. 125, 560-567 (2012).
16. Burn J, Gerdes AM, Macrae F et al. Long-term effect of aspirin on cancer in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised trial. Lancet 377, 2081-2087 (2010).
17. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomised clinical trial of faecal occult blood screening for colorectal cancer. Br. J. Surg. 95, 1029-1036 (2008).
18. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the faecal occult blood test (haemoccult): An update. Am. J. Gastroenterol. 103, 1541-1549 (2008).
19. Atkin WS, Edwards R, Kralj-Hans I et al. Once only flexible sigmoidoscopy screening in prevention of colorectal cancer: A multicentre randomised controlled trial. Lancet 375, 1624-1633 (2010).
20. Singh H, Nugent Z, Demers AA, Bernstein CN. Rate and predictors of early/missed colorectal cancers after colonoscopy in Manitoba: A population-based study. Am. J. Gastroenterol. 105, 2588-2596 (2010).
21. Logan RF, Patnick J, Nickerson C et al. Outcomes of the bowel cancer screening programme (BCSP) in England after the first 1 million tests. Gut 61(10), 1439-1446 (2011).
22. Aviva D, Moshkowitz M, Detering E, Arber N. The role of low-dose aspirin in the prevention of colorectal cancer. Expert Opin. Ther. Targets 16(Suppl. 1), S51-S62 (2012).
23. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials. Lancet 13, 518-527 (2012).
24. Mahipal A, Anderson KE, Limberg PJ, Folwom AR. Non-steroidal anti-inflammatory drugs and sub-site specific colorectal cancer incidence in the Iowa Women's Health Study. Cancer Epidemiol. Biomarkers Prev. 15, 1785-1790 (2006).
25. Ruder EH, Laiyemo AO, Graubard BI. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am. J. Gastroenterol. 106, 1340-1350 (2011).
26. Charames GS, Bapat B. Genomic instability and cancer. Curr. Mol. Med. 3, 589-596 (2003).
27. Chung YM, Bae YS, Lee SY. Molecular ordering of ROS production, mitochondrial changes, and caspase activation during sodium salicylate-induced apoptosis. Free Radic. Biol. Med. 34, 434-442 (2003).
28. Mahdi JG, Alkarrawi MA, Mahdi AJ, Bowen ID, Humam D. Calcium salicylate-mediated apoptosis in human HT01080 fibrosarcoma cells. Cell Prolif. 39, 249-260 (2006).
29. Ruschoff J, Wallinger S, Dietmaier W et al. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc. Natl Acad. Sci. USA 95, 11301-11306 (1998).
30. Goel A, Chang DK, Ricciardiello L, Gasche C, Boland CR. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin. Cancer Res. 9, 383-390 (2003).
31. Giovannucci E, Egan KM, Hunter DJ et al. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333, 609-614 (1995).
32. Gasic GJ, Gasic TB, Stewart CC. Anti-metastatic effects associated with platelet reduction. Proc. Natl Acad. Sci. USA 6, 46-52 (1968).
33. Gasic GJ, Gasic TB, Stewart CC. Anti-metastatic effect of aspirin. Lancet 2, 932-933 (1973).
34. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302, 649-659 (2009).
35. McCowan C, Munro AJ, Donnan PT, Steele RJ. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal specific mortality. Eur. J. Cancer 49, 1049-1057 (2013).
36. Bastiaannet E, Sampieri K, Dekkers OM et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br. J. Cancer 106, 1564-1570 (2012).
37. Stürmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians Health Study. Ann. Intern. Med. 128, 713-720 (1998).
38. Cook NR, Lee I-Min, Zang SM et al. Alternate-day low-dose aspirin and cancer risk: Long-term observational follow-up of a randomized trial. Ann. Intern. Med. 159, 77-85 (2013).
39. Seshasai SR, Wejesuriya S, Sivakumaran R et al. Effect of asirin on vascular and non-vascular outcomes: Meta-analysis of randomised controlled trials. Arch. Intern. Med. 172, 209-216 (2012).
40. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegleman D, Hankinson SE. Aspirin intake and survival after breast cancer. J. Clin. Oncol. 28, 1467-1472 (2010).
41. Fontaine E, McShane J, Page R et al. Aspirin and non-small cell lung cancer resections: Effect on long-term survival. Eur. J. Cardiothorac. Surg. 38, 21-26 (2010).
42. Liu JF, Jamieson GG, Wu TC, Zhu GJ, Drew PA. A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. Ann. Surg. Oncol. 16, 1397-1402 (2009).
43. Xia D, Wang D, Kim SH, Katoh H, DuBois RN. Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat. Med. 18, 224-226 (2012).
44. Nishishara R, Lochhead P, Kychiba A et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. J. Am. Med. Assoc. 309, 2563-2571 (2013).
45. Liao X, Lochhead P, Nishihara R et al. Aspirin use, tumor PIK3CA mutation and colorectal-cancer survival. N. Engl. J. Med. 367, 1596-1606 (2012).
46. Liberman D. Progress and challenges in colorectal screening and surveillance. Gastroenterology 138, 2115-2126 (2010).
47. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849-1860 (2009).
48. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherosclerosis. N. Engl. J. Med. 353, 2373-2383 (2005).
49. McQuaid KR, Laine LS. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am. J. Med. 119, 624-638 (2006).
50. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sáinz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol. Ther. 16, 779-786 (2002).
51. Laine L, Maller ES, Yu C, Quank H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double blind trial. Gastroenterology 127, 385-402 (2004).
52. Brown LM. Helicobacter pylori: Epidemiology and routes of transmission. Epidemiol. Rev. 22, 283-297 (2000).
53. Chan KL, Chung SC, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med. 344, 967-973 (2001).
54. Morgan G Aspirin for the primary prevention of vascular events? Public Health 123, 787-788 (2009).
55. Lanas A, Perez-Aisa MA, Feu F et al. A nationwide study of mortality associated with hospital admission due to severe GI events and those associated with NSAID use. Am. J. Gastroenterol. 100, 1685-1693 (2005).
56. Chan FK, Goto S, Wu MS et al. Burden of nonsteroidal anti-inflammatory and antiplatelet drug use in Asia: A multidisciplinary working party report. Clin. Gastroenterol. Hepatol. 10(7), 753-760 (2012).
57. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as a cause of admission to hospital: Retrospective analysis of 18,820 patients. BMJ 329, 15-19 (2004).
58. Graham DY, Smith JL, Dobbs SM. Gastric adaption occurs with aspirin administration in man. Digest. Dis. Sci. 28, 1-6 (1983).
59. Garcia Rodriguez LA, Hermandez S, de Abajo J. Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiologic studies. Br. J. Clin. Pharmacol. 52, 563-571 (2001).
60. Würtz M, Grove EL. Combining aspirin and proton pump inhibitors: For whom the warning bell tolls? Expert Opin. Drug Metab. Toxicol. 8, 1051-1055 (2012).
61. Targownik LE, Metge CJ, Leung S. Underutilization of gastroprotective strategies in aspirin users at increased risk of upper gastrointestinal complications. Aliment Pharmacol. Ther. 28, 2888-2896 (2008).
62. Derogar M, Sandblom G, Lundell L et al. Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events. Clin. Gastroenterol. Hepatol. 11, 38-42 (2012).
63. Biondi-Zoccai GG, Lotrionte M, Agostoni P et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur. Heart J. 27, 2667-2674 (2006).
64. Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischaemic stroke. Arch. Neurol. 62, 1217-1220 (2005).
65. Sung JJ, Ching JY, Wu LC et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: A randomised trial. Ann. Intern. Med. 152, 1-9 (2010).
66. Boustiere C, Veitch A, Vanbiervilet G et al. Endoscopy and antiplatelet agents. European Society of Gastrointetinal Endoscopy Guideline. Endoscopy 43, 445-448 (2011).
67. Gorlick PB, Weisman SM. Risk of haemorrhagic stroke with aspirin use: An update. Stroke 36, 1801-1807 (2005).
68. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) trial. HOT study group. Lancet 351, 1755-1762 (1998).
69. Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer carrier: A 20 year follow-up. Gut 61, 1036-1040 (2012).
70. Schoen RE, Pinsky PF, Weissfeld JL et al. Colorectal cancer incidence and mortality with screening flexible sigmoidscopy. N. Engl. J. Med. 366, 2345-2357 (2012).
71. Newby LK, Manjushri V, Bhapkar MS et al. Aspirin use post acute coronary syndromes: Intolerandce, bleeding and discontinuation. J. Thromb. Thrombolysis 16, 119-128 (2003).
72. Morgan G. Rapid health impact assessment of aspirin promotion for the secondary prophylaxis of vascular events in Wales. Qual. Prim. Care 20, 299-301 (2012).
73. van Soest EM, Sturkenboom MC, Dieleman JP, Verhamme KM, Siersema PD, Kuipers EJ. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol. Ther. 26, 265-275 (2007).
74. Hassan C, Rex DK, Cooper GS, Zullo A, Launois R, Benamouzig R. Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: A cost-effectiveness analysis. Gut 61, 1172-1179 (2012).
75. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic and clinical issues. J. Natl Cancer Inst. 94, 252-266 (2002).
76. Pignone M, Earnshaw S, McDade C, Pletcher MJ. Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men. J. Gen. Intern. Med. doi:10.1007/s11606-013-2465-6 (2013) (Epub ahead of print).
77. Sandler RS, Halabi S, Baron JA et al. A randomised trial of aspirin to prevent colorectal adenoma in patients with previous colorectal cancer. N. Engl. J. Med. 348, 883-890 (2003).
78. Baron JA, Cole BF, Sandler RS et al. A randomised trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348, 891-899 (2003).
79. Courtney RJ, Paul CL, Sanson-Fisher R, Carey M, Macrae FA, Yoong SL. Community approaches to increasing colorectal screening uptake: A review of the methodological quality and strength of current evidence. Cancer Forum 36, 27-35 (2012).
80. Smith SK, Trevena L, Simpson JM, Barratt A, Nutbeam D, McCaffery KJ. A decision aid to support informed choices about bowel cancer screening among adults with low education: Randomised controlled trial. BMJ 341, c5370 (2010).
81. Kahi CJ, Imperiale TF. Do aspirin and nonsteroidal anti-inflammatory drugs cause false-positive fecal occult blood test results? A prospective study in a cohort of veterans. Am. J. Med. 117, 837-841 (2004).
82. Brenner H, Tao S, Haug U. Low-dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA 304, 2513-2520 (2010).
83. Elwood P, Morgan GP, Brown G, Pickering J Aspirin for all over 50? BMJ 330, 1440-1442 (2005).
84. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N. Engl. J. Med. 343, 16-22 (2000).
85. Hu FB, Manson JE, Stampfer MJ et al. Diet, lifestyle and the rise of Type 2 diabetes in women. N. Engl. J. Med. 345, 790-797 (2001).
86. Chiuve SE, McCullough ML, Sacks FM, Rimm EB. Healthy lifestyle factors in the primary prevention of coronary heart disease among men: Benefits among users and non-users of lipid lowering and antihypertensive medications. Circulation 114, 160-167 (2006).
87. Kvaavik E, Batty D, Ursin G, Huxley R, Gale CR. Influence of individual and combined health behaviors on total and cause-specific mortality in men and women: The United Kingdom health and lifestyle survey. Arch. Intern. Med. 170, 711-718 (2010).
88. McCullough ML, Patel AV, Kushi LH et al. Following cancer prevention guidelines reduces risk of cancer, cardiovascular disease and all-cause mortality. Cancer Epidemiol. Biomarkers Prev. 20, 1089-1097 (2001).
89. Kirkegaard H, Johnsen NF, Christensen J, Frederiksen K, Overvad K, Tjønneland A. Association of adherence to lifestyle recommendations and risk of colorectal cancer: A prospective Danish cohort study. BMJ 341, c5504 (2010).
90. Meyerhardt JA. Beyond standard adjuvant therapy for colon cancer: Role of nonstandard interventions. Semin. Oncol. 38, 533-541 (2011).
91. Elwood PC, White J, Fone D et al. Aspirin taking in the community: A cross-sectional survey. Br. J. Cardiol. 18, 238-230 (2012).
92. Hale J, Phillips CJ, Jewel T. Making the economic case for prevention - a view from Wales. Public Health 12, 460-469 (2012).
93. Ajani UA, Ford ES, Greenland KJ. Aspirin use among US adults: Behavioural risk factor surveillance system. Am. J. Prev. Med. 30, 74-77 (2006).
94. Elwood PC, Longley M. My health - whose responsibility - a jury decides. J. Epidemiol. Community Health 64, 761-764 (2010).
95. Waller J, Macedo A, von Wagner C et al. Communication about colorectal cancer screening in Britain: Public preferences for an expert recommendation. Br. J. Cancer 107, 1938-1943 (2012).
96. Chan AT, Arber N, Burn et al. Aspirin in the chemoprevention of colorectal neoplasia: An overview. Cancer Prev. Res. 5, 164-178 (2011).
97. Wanless D. Securing Good Health for the Whole Population. HM Treasury, London, UK (2004).
98. Choosing Health: Making Healthier Choices Easier. A Public Health 'White Paper'. Department of Health, London, UK (2004).
99. Public Attitudes to Public Health Policy. King's Fund, London, UK (2004).
100. Equity and Excellence: Liberating the NHS. Cm 7881. Department of Health, London, UK (2010).